

Supplementary Table 4. Comparison of Demographic and Clinical Characteristics between Non-Enhanced Treatment Group and Enhanced Treatment Group

Variable	Non-enhanced treatment group (n = 30)	Enhanced treatment group (n = 43)	P-value
Age at diagnosis (yr)	38 (14–47)	30 (13–68)	0.592
Sex, male:female	21:9	35:8	0.281
Body mass index (kg/m ²)	21.0 (15.6–32.5)	20.4 (15.0–29.6)	0.667
Disease duration (yr)	11 (0–36)	3 (0–36)	0.039
Previous bowel resection	10 (33.3)	9 (20.9)	0.234
Perianal disease	10 (33.3)	20 (46.5)	0.260
Current smoking	4 (13.3)	14 (32.6)	0.061
Disease phenotype			
B1 (inflammatory)	14 (46.7)	17 (39.5)	0.544
B2 (stricturing)	10 (33.3)	17 (39.5)	0.589
B3 (penetrating)	6 (20.0)	9 (20.9)	0.922
Crohn's Disease Activity Index	69 (14–143)	76 (15–143)	0.013
Concomitant medication for CD			
Enteral nutrition	13 (43.3)	17 (39.5)	0.745
5-Aminosalicylic acid	18 (60.0)	22 (51.2)	0.455
Corticosteroid	1 (3.3)	1 (2.3)	0.795
Immunomodulator	6 (20.0)	7 (16.3)	0.683
Infliximab	16 (53.3)	10 (23.3)	0.011
Adalimumab	3 (10.0)	4 (9.3)	0.921
Ustekinumab	0	2 (4.7)	0.231
US-CD	4 (0–42)	10 (1–38)	0.011

Values are presented as median (range) or number (%).

CD, Crohn's disease; US, ultrasonography.

P-values were calculated using the Mann-Whitney *U* test for continuous variables and chi-square test for categorical data.